NephrologyOnline.net

Nephrology Xagena

Hypertension is common in autosomal dominant polycystic kidney disease ( ADPKD ) and is associated with increased total kidney volume, activation of the renin–angiotensin–aldosterone system, and progr ...


Oral anticoagulation therapy ( OAT ) is the choice treatment for thromboembolism prevention in atrial fibrillation ( AF ), although data about oral anticoagulants use in haemodialysis ( HD ) patients ...


Abnormal mineral metabolism is a hallmark in patients with advanced chronic kidney disease ( CKD ). Hyperphosphatemia, and the homeostatic mechanisms controlling phosphate metabolism, have received pa ...


Fibroblast growth factor 23 ( FGF23 ) and Klotho are associated with vascular calcification and cardiovascular disease in dialysis patients. Sevelamer ( Renagel, Renvela ) has been shown to reduce p ...


Serum Alkaline phosphatase ( ALP ) & phosphate are considered to be indicators of vascular calcification. Link between bone metabolism, vascular calcification, cardiovascular events have been well ...


A study has assessed the effects and safety of iron-based phosphate binders in adult patients receiving dialysis. Eight studies with 2018 participants were eligible for the meta-analysis. Iron- ...


The concept of chronic kidney disease - mineral bone disorder ( CKD-MBD ) does not appear to fulfil the requirements for a syndrome at first glance, but its definition has brought some clear-cut benef ...


Reduction of dietary sodium intake or diuretic treatment increases renin-angiotensin-aldosterone system ( RAAS ) blockade efficacy in non-diabetic nephropathy. A study has investigated the effect of ...


Risk of end-stage renal disease ( ESRD ) in kidney donors has been compared with risk faced by the general population, but the general population represents an unscreened, high-risk comparator. A co ...


Peritoneal dialysis is the renal replacement therapy of choice for acute kidney injury in neonates, but in some cases is not feasible or effective. Continuous renal replacement therapy ( CRRT ) machin ...


The two largest studies of mammalian target of rapamycin inhibitor treatment of autosomal dominant polycystic kidney disease ( ADPKD ) have demonstrated no clear benefit on the primary endpoint of tot ...


In phase 4 IMPACT-SHPT study, efficacy and safety of Paricalcitol-centred therapy were compared with that of Cinacalcet-centred therapy for the treatment of chronic kidney disease (CKD)-associated sec ...


In autosomal dominant polycystic kidney disease ( ADPKD ), progressive kidney cyst formation commonly leads to end-stage renal disease ( ESRD ). Because important manifestations of ADPKD may be evid ...


The role of hyperuricemia in disease progression of autosomal dominant polycystic kidney disease ( ADPKD ) has not been defined well. Researchers have investigated the association of serum uric acid ...


Autosomal dominant polycystic kidney disease ( ADPKD ) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to ...